Deep-pocketed investors have adopted a bullish approach towards Novo Nordisk (NYSE:NVO), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in NVO usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 22 extraordinary options activities for Novo Nordisk. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 50% leaning bullish and 31% bearish. Among these notable options, 9 are puts, totaling $571,820, and 13 are calls, amounting to $1,045,859.
Projected Price Targets
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $45.0 to $170.0 for Novo Nordisk over the recent three months.
Insights into Volume & Open Interest
Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Novo Nordisk's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Novo Nordisk's whale trades within a strike price range from $45.0 to $170.0 in the last 30 days.
Novo Nordisk Call and Put Volume: 30-Day Overview
Significant Options Trades Detected:
| Symbol | PUT/CALL | Trade Type | Sentiment | Exp. Date | Ask | Bid | Price | Strike Price | Total Trade Price | Open Interest | Volume |
|---|
| NVO | CALL | TRADE | BEARISH | 02/21/25 | $2.0 | $1.93 | $1.94 | $95.00 | $397.7K | 1.1K | 2.1K |
| NVO | CALL | SWEEP | BULLISH | 01/16/26 | $13.1 | $13.05 | $13.1 | $87.50 | $217.4K | 69 | 205 |
| NVO | PUT | SWEEP | BULLISH | 02/21/25 | $34.75 | $33.1 | $33.6 | $120.00 | $165.8K | 0 | 50 |
| NVO | CALL | SWEEP | BEARISH | 01/17/25 | $5.1 | $4.95 | $4.96 | $82.50 | $99.2K | 1.1K | 201 |
| NVO | PUT | TRADE | BULLISH | 01/16/26 | $85.2 | $83.65 | $83.68 | $170.00 | $83.6K | 10 | 10 |
About Novo Nordisk
With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting roughly 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
After a thorough review of the options trading surrounding Novo Nordisk, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
Novo Nordisk's Current Market Status
- With a volume of 3,808,605, the price of NVO is down -1.21% at $86.31.
- RSI indicators hint that the underlying stock may be oversold.
- Next earnings are expected to be released in 37 days.
What The Experts Say On Novo Nordisk
1 market experts have recently issued ratings for this stock, with a consensus target price of $105.0.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. Click here for access.* An analyst from BMO Capital has decided to maintain their Outperform rating on Novo Nordisk, which currently sits at a price target of $105.
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
财力雄厚的投资者对诺和诺德（纽约证券交易所代码：NVO）采取了看涨态度，这是市场参与者不容忽视的。我们对本辛加公开期权记录的追踪今天揭示了这一重大举措。这些投资者的身份仍然未知，但是NVO的如此实质性的变动通常表明重大事件即将发生。
我们今天从观察中收集了这些信息，当时Benzinga的期权扫描仪重点介绍了诺和诺德的22项非同寻常的期权活动。这种活动水平与众不同。
这些重量级投资者的总体情绪存在分歧，50％的人倾向于看涨，31％的人看跌。在这些值得注意的期权中，有9个是看跌期权，总额为571,820美元，13个是看涨期权，总额为1,045,859美元。
预计的目标价格
根据交易活动，看来重要投资者的目标是在最近三个月中将Novo Nordisk的价格范围从45.0美元扩大到170.0美元。
对交易量和未平仓合约的见解
交易期权时，查看交易量和未平仓合约是一个强有力的举动。这些数据可以帮助您跟踪Novo Nordisk期权在给定行使价下的流动性和利息。下面，我们可以观察过去30天内诺和诺德所有鲸鱼交易的看涨和看跌期权交易量和未平仓合约的变化，其行使价在45.0美元至170.0美元之间。
Novo Nordisk 看涨和看跌交易量：30 天概述
检测到的重大期权交易：
Symbol | PUT/CALL | Trade Type | Sentiment | Exp. Date | Ask | Bid | Price | Strike Price | Total Trade Price | Open Interest | Volume |
|---|
NVO | CALL | TRADE | BEARISH | 02/21/25 | $2.0 | $1.93 | $1.94 | $95.00 | $397.7K | 1.1K | 2.1K |
NVO | CALL | SWEEP | BULLISH | 01/16/26 | $13.1 | $13.05 | $13.1 | $87.50 | $217.4K | 69 | 205 |
NVO | PUT | SWEEP | BULLISH | 02/21/25 | $34.75 | $33.1 | $33.6 | $120.00 | $165.8K | 0 | 50 |
NVO | CALL | SWEEP | BEARISH | 01/17/25 | $5.1 | $4.95 | $4.96 | $82.50 | $99.2K | 1.1K | 201 |
NVO | PUT | TRADE | BULLISH | 01/16/26 | $85.2 | $83.65 | $83.68 | $170.00 | $83.6K | | |
关于诺和诺德
Novo Nordisk拥有全球品牌糖尿病治疗市场约三分之一的份额，是全球领先的糖尿病护理产品提供商。该公司总部位于丹麦，生产和销售各种人类和现代胰岛素、可注射的糖尿病治疗药物，例如 GLP-1 疗法、口服抗糖尿病药物和肥胖疗法。Novo还有一个生物制药板块（约占收入的10％），专门从事血友病和其他疾病的蛋白质疗法。
在对围绕Novo Nordisk的期权交易进行了全面审查之后，我们将对该公司进行更详细的审查。这包括评估其当前的市场状况和表现。
诺和诺德的当前市场状况
专家对诺和诺德的看法
1位市场专家最近发布了该股的评级，共识目标价为105.0美元。
检测到不寻常的期权活动：智能货币在移动
Benzinga Edge的不寻常期权委员会在潜在的市场推动者发生之前就发现了它们。看看大笔资金对你最喜欢的股票持有哪些头寸。点击此处查看。* BMO Capital的一位分析师已决定维持对Novo Nordisk的跑赢大盘评级，该评级目前的目标股价为105美元。
与仅交易股票相比，期权是一种风险更高的资产，但它们具有更高的盈利潜力。严肃的期权交易者通过每天进行自我教育、扩大交易规模、遵循多个指标以及密切关注市场来管理这种风险。
